DAVION HEALTHCARE ANNOUNCES PROPOSED ACQUISITION OF HUMASKAN AND ESTABLISHMENT OF UK FINANCE SUBSIDIARY TO SUPPORT STRATEGIC ACQUISITION PROGRAMME

Davion Healthcare Plc has announced the acquisition of Humaskan Ltd for a total consideration of $60 million, comprising $10 million in cash and $50 million in equity. The transaction, formalized through a share purchase agreement, was disclosed on June 25, 2026. The equity component is set at a reference price of $13.00 per share, which will be subject to a nine-month lock-up period, allowing for an orderly market disposal thereafter.

Humaskan Ltd is a medical technology company known for its proprietary healthcare products and intellectual property. The acquisition aligns with Davion Healthcare's strategy of expanding its digital healthcare platform, which focuses on non-invasive remote health monitoring solutions aimed at the early identification of medical anomalies. This move follows Davion's recent acquisition of Solar Medical and Chemical Limited, which is intended to bolster its commercial and distribution capabilities in the United Kingdom.

The strategic rationale behind acquiring Humaskan is multifaceted. By integrating Humaskan's innovative technologies and intellectual property, Davion aims to enhance its product development and manufacturing capabilities. This acquisition is expected to create additional revenue growth avenues and support further expansion within the healthcare sector across the United States and Europe. Furthermore, the transaction underscores Davion's commitment to disciplined capital deployment and strategic financing initiatives.

To facilitate its acquisition strategy, Davion plans to establish a wholly owned subsidiary, Davion Healthcare Finance Ltd, which will support the company's financing needs. The subsidiary is expected to initiate a corporate bond program of up to £100 million, structured to appeal to professional and institutional investors. This financing initiative will provide Davion with the flexibility to pursue additional acquisition opportunities and strengthen its overall healthcare platform.

The broader market implications of this acquisition and the associated financing strategy suggest a growing trend of consolidation within the healthcare sector. As companies seek to enhance their technological capabilities and expand their market presence, strategic acquisitions like that of Humaskan will likely become more prevalent. Davion's proactive approach in establishing a robust financing mechanism indicates a forward-looking strategy that aims to position the company for sustained growth and competitiveness in the evolving healthcare landscape.